

Appendix 4C

Quarter Ended 31 December 2021

Chimeric Therapeutics Limited

ACN 638 835 828

ASX: CHM

ASX ANNOUNCEMENT **27 JANUARY 2022**

QUARTERLY ACTIVITES REPORT FOR THE PERIOD ENDING 31 DECEMBER 2021

Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), the ASX leader in cell therapy, is pleased to provide a summary of its activities for the quarter ended 31 December 2021.

Key highlights for the quarter included:

- Exclusive option to licence transformative CORE-NK platform obtained, enabling the accelerated development of multiple next generation NK and CAR-NK products
- Four new Chimeric assets to initiate development beginning in 2022, leveraging the company's existing portfolio of CARs
- Initial positive phase 1 clinical data presented for lowest dose level (44 X 10^6 CLTX CAR T cells), with therapy generally well tolerated and a 75% disease control rate for up to 8 weeks
- Completion of CLTX CAR T dose level 2 with no dose limiting toxicities ; dose level 3 enrollment open
- Manufacturing for CHM 2101 research grade plasmids successfully completed, a critical first step in the development of CDH17 CAR T
- Dr Eliot Bourk promoted to role of Chief Business Officer (CBO) and Head of External Innovation

Chimeric expands portfolio with CORE-NK cell platform

In December, Chimeric entered into an exclusive option to license agreement with Case Western Reserve University (CWRU) for a clinically validated, off the shelf, robust, enhanced natural killer (CORE-NK) cell platform. The platform is a transformative technology which enables the development of multiple next generation NK and CAR-NK products through internal development and/or partnerships with other biotech and pharmaceutical companies.

The platform was studied in a phase 1 clinical trial completed in June 2021 in both solid tumours and blood cancers with clinical data expected in 2022. The trial examined the safety, bioactivity and efficacy of the CORE-NK platform cells at three dose levels in patients with both blood cancers and solid tumours.

Four new Chimeric assets will initiate development in 2022 using the company's existing portfolio of CARs, with initial clinical trials planned for 2023 to investigate blood cancers and solid tumours.

The next generation platform will be developed with enhanced activation and expansion features with plans to study it as a combination therapy in blood cancers.

Chimeric has the exclusive right to license the CORE-NK platform for development and commercialisation in cancer under the terms of the agreement. The Company intends to rapidly move to complete full licensing of the platform and expects to pay CWRU development milestones and industry standard royalty payments based on commercial net sales.

Initial Phase 1 clinical data & further progress in CLTX CAR T trial

In November, two CLTX CAR T abstracts were presented at the Society for Neuro Oncology annual scientific meeting, showing initial positive results from the initial dose cohort of the CLTX CAR T phase 1 clinical trial.

Patients receiving dose level 1 (44 X 10^6 CLTX CAR T cells) showed a disease control rate of 75%, with three of the four patients treated achieving a best response of stable disease assessed by RANO (response assessment in neuro-oncology). Addition details demonstrated that the disease control observed was durable for approximately 5-8 weeks.

In one patient it was observed that tumour recurrence was prevented at the site where CLTX CAR T cells were infused, while progression occurred at sites that did not receive the infusion. In addition, the treatment was generally well tolerated with no dose-limiting toxicities and no observed cytokine release syndrome (CRS).

Bioactivity of the cells was also demonstrated as liquid biopsy detected CLTX CAR T cells in the tumour cavity throughout treatment, suggesting that CLTX CAR T cells do not trigger an immune response that impacts the treatment's persistence and efficacy.

The 2nd dose cohort of the Phase 1 trial was completed in December, with all patients advancing past the 28 day follow up period with no dose-limiting toxicities. The study has advanced to the 3rd dose cohort, which will administer CLTX CAR T cells to patients through the dual routes of administration at an increased total dose of 220 X 10^6 CLTX CAR T cells.

First milestone reached on path to CDH17 CAR T clinical trial

In October, the Company completed the manufacturing for CHM 2101 research-grade plasmids, a critical first step in developing CDH17 CAR T. This has enabled progression to research vector manufacturing, GMP plasmid and vector manufacturing and advancement of technical operations in readiness for the CDH17 phase 1 clinical trial.

The manufacturing of CAR T therapies depends on plasmids and viral vectors that hold the genetic instructions for each specific CAR T product. Plasmids are small DNA molecules that carry genetic instructions, and their successful manufacture marks an essential early step for all CAR T therapies.

Key management changes for 2022

During the quarter former Vice President Business and Corporate Development Dr Eliot Bourk was promoted to the role of Chief Business Officer (CBO) and Head of External Innovation, where he continues to lead business and corporate development for Chimeric while also taking the extended responsibility for Chimeric's early scientific strategy.

Chimeric Chief Medical Officer Dr Syed Rizvi left the Company following the completion of his 12-month contract. The board thanks him for his important contributions at a pivotal stage.

Annual General Meeting

The 2021 Annual General Meeting of Chimeric Therapeutics Ltd was held during the quarter, with all resolutions put to shareholders being carried.

Click here to view the corporate update from CEO and Managing Director Jennifer Chow that was delivered at the Meeting.

Financial Update

An Appendix 4C is attached to this announcement.

As detailed in the attached ASX Appendix 4C, the Company had $13.4 million in cash and equivalents as at 31 December 2021, down from $17.4 million compared to 30 September 2021. This will support the Company's efforts to progress the development of CLTX CAR T and initiate the development of a cell therapy pipeline.

The net cash used in operating activities during the quarter was $3.9 million compared to $2.5 million for the quarter to 30 September 2021. The increase is mainly due to the commencement of payments to the CLTX CRO for Phase 1 trials.

In accordance with Listing Rule 4.7C, payments made to related parties and their associates included in items 6.1 of the Appendix 4C include payments for remuneration of director fees to executive and non-executive directors in the normal course of business at commercial rates, excluding reimbursements of out-of-pocket expenses.

Pursuant to Listing Rule 4.7C.2, the Company confirms that, in the 12 months since listing on the ASX, it has incurred expenditure largely in line with the Use of Proceeds set out in its Prospectus, as detailed below.

Use of Funds under Prospectus	Funds allocated under Prospectus	Funds expected allocation between admission and 31 Dec 2021	Funds expended between admission and 31 Dec 2021	Variance	
Offer Costs[1]	$2,918,758	$2,918,758	$2,663,979	$254,779	9%
Admin, Corporate and general working capital[2]	$5,454,318	$5,013,967	$6,053,785	($1,039,818)	(21%)
Employment[2]	$5,714,163	$4,012,018	$4,801,317	($789,299)	(20%)
Licence Fees to City of Hope[1]	$6,966,611	$4,861,111	$4,628,694	$232,417	5%
Research and Development on other cancer targets[3]	$5,601,101	$4,041,664	$1,960,503	$2,081,161	51%
Phase 1 clinical trial and manufacturing[3]	$1,875,006	$1,250,004	$0	$1,250,004	100%
Opening new additional Phase 1 sites[1]	$5,000,000	$0	$0	$0	0%
Other commercial and academic collaborations	$5,000,000	$934,000	$924,579	$9,421	1%
Total	**$38,529,957**	**$23,031,522**	**$21,032,857**	**$1,998,665**	**9%**

[1] Costs remain in line with expected use of funds.
[2] Increased expenditure relates to hiring additional employees and engaging in additional corporate activities.
[3] Costs incurred are lower than forecast. Delays in R&D due to staffing challenges during the pandemic.

Authorised by the Chimeric Therapeutics board of directors.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and the ASX leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed by scientists at the City of Hope Medical Centre in California for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in recurrent/ progressive glioblastoma. A 2nd CLTX CAR T phase 1 clinical trial is planned to begin in 2022 in additional solid tumours.

CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the University of Pennsylvania. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in 2022 in Neuroendocrine Tumours, Colorectal, Pancreatic and Gastric Cancer.

Recently Chimeric announced the addition of the CORE-NK platform, a clinically validated, off the shelf natural killer (NK) cell therapy platform to their portfolio (CHM 0201). From the CORE-NK platform, Chimeric will initiate development of four new next generation NK and CAR NK assets with plans for phase 1 clinical trials to begin in 2023 in solid tumours and blood cancers.

Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.

CONTACT

Investors

Jennifer Chow
Chief Executive Officer and Managing Director
Chimeric Therapeutics
T: + 1 9087238387
E: jchow@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Paul Hopper
Executive Chairman
Chimeric Therapeutics
T: + 61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media

Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Chimeric Therapeutics Limited

ABN	**Quarter ended ("current quarter")**
68 638 835 828	31 December 2021

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (6 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	-	-
1.2	Payments for		
	(a) research and development	(1,501)	(2,126)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	-	-
	(d) leased assets	-	-
	(e) staff costs	(1,706)	(3,192)
	(f) administration and corporate costs	(816)	(1,190)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	3	8
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	30	52
1.9	**Net cash from / (used in) operating activities**	**(3,990)**	**(6,448)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	(6)
	(d) investments	-	-
	(e) intellectual property	-	(478)
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (6 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**-**	**(484)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other – repayment of debt	-	(2,041)
3.10	**Net cash from / (used in) financing activities**	**-**	**(2,041)**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	17,421	22,410
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(3,990)	(6,448)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	(484)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (6 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	(2,041)
4.5	Effect of movement in exchange rates on cash held	1	(5)
4.6	**Cash and cash equivalents at end of period**	**13,421**	**13,431**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	2,889	6,921
5.2	Call deposits	10,542	10,500
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**13,431**	**17,421**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	632
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

Item 6.1 – Include payments for remuneration of director fees to executive and non-executive directors in the normal course of business at commercial rates, excluding reimbursements of out-of-pocket expenses.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

N/A

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(3,990)
8.2	Cash and cash equivalents at quarter end (item 4.6)	13,431
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	13,431
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	3.4

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 27 January 2022

Authorised by: The Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

Phone +61 3 98245254
Email info@chimerictherapeutics.com

Chimeric Therapeutics Limited

ACN 638 835 828

ASX: CHM

CHIMERIC
THERAPEUTICS